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 Abstract 
 
Communication problems are a frequent symptom for people with Parkinson‟s disease (PD) 
which can have a significant impact on their quality of life. Deciding on the right 
management approach can be problematic though, as, with the exception of LSVT
®
, very few 
studies have been published demonstrating the effectiveness of treatment techniques. The aim 
of this study was to compare traditional rate reduction methods with altered auditory 
feedback (AAF) with respect to their effectiveness to reduce speech rate and improve 
intelligibility in speakers with PD. Ten participants underwent both types of treatments in 
once weekly sessions for 6 weeks. Outcomes measures were speech rate for passage reading 
as well as intelligibility on both a passage reading and a monologue task. The results showed 
that as a group, there was no significant change in either speech rate or intelligibility resulting 
from either treatment type. However, individual speakers showed improvements in speech 
performance as a result of each therapy technique. In most cases, these benefits persisted for 
at least 6 months post-treatment. Possible reasons for the variable response to treatment, as 
well issues to consider when considering using AAF devices in treatment are discussed. 
Introduction 
Loss of speech intelligibility is one of the major concerns of people with Parkinson‟s disease 
(PwPD) (Miller, Noble, Jones, & Burn, 2006). The main changes in speech that are 
frequently described in the literature are reductions in vocal loudness, articulatory deficits 
and changes in speech rate. Most of the medical treatments available for Parkinson‟s disease 
(PD) show little improvement for speech compared to gross motor movements (Ramig, Fox 
& Sapir, 2004). Treatment for speech impairments is thus still largely based on behavioural 
techniques. Amongst these, the Lee Silverman Voice Treatment (LSVT
®
) is a treatment 
programme that has proved to be highly effective in addressing loudness deficits (Ramig et 
al., 2001) with carryover to other features of PD speech disturbance such as articulatory 
deficits (Dromey, Ramig & Johnson, 1995; Ramig et al., 2004). However, although efficacy 
studies included participants with a range of dysarthria severities, anecdotal evidence 
suggests that clinicians often perceive this treatment as being more appropriate for clients at 
the milder end of the severity spectrum due to the physical and cognitive demands associated 
with the treatment regime. Treatment for clients with moderate to severe dysarthria thus still 
relies on rate control techniques to improve a speaker‟s intelligibility. A number of strategies 
for rate reduction are described in the literature, such as pacing by finger tapping and using a 
pacing board or a metronome (Yorkston, Beukelman, Strand, & Bell, 1999). Less impaired 
speakers are frequently asked to pace themselves without external aids. Although a number of 
case studies suggest that such techniques can be useful (Hammen, Yorkston, & Minifie, 
1994; Helm, 1979; Le Dorze, Dionne, Ryalls, Julien, & Ouellet, 1992; Yorkston, Hammen, 
Beukelman, & Traynor, 1990), there is no conclusive evidence for the effectiveness of rate 
reduction therapy in speakers who have PD, particularly in relation to long term effects and 
carry over into everyday speech (Deane, Whurr, Playford, Ben-Shlomo, & Clarke, 2001a, 
2001b). In addition, the relationship between a reduction in speech rate and intelligibility is 
not always straightforward (Van Nuffelen, De Bodt, Wuyts, & Van de Heyning, 2009; Van 
Nuffelen, De Bodt, Vanderwegen, Van de Heyning, Wuyts, 2010). 
Altered auditory feedback (AAF) is an alternative method to traditional rate control 
techniques which can be used to help reduce speaking rate. The method was originally 
developed for people who stutter (PwS). The speaker wears a device through which they hear 
their speech in an altered fashion. This disrupts the normal auditory feedback loop which 
causes the speaker to slow down. There are several types of AAF: delayed auditory feedback 
(DAF) delivers the speech signal to the speaker after a short delay (usually between 50 and 
200 ms); frequency shifted feedback (FSF) delivers the speech signal in real time but with an 
altered pitch (up to 1 octave up or downward shift); and masking blocks out the auditory 
feedback signal. In addition, DAF and FSF can be used in combination with each other. 
Initial reports on DAF‟s effects in PwPD were published in the 1980s and 1990s (Adams, 
1994; Downie, Low, & Lindsay, 1981; Hanson & Metter, 1983; Yorkston et al., 1999) and 
more recently by Van Nuffelen et al. (2009, 2010). Although these studies generally reported 
benefits for speech rate and intelligibility, it also became evident that speakers‟ responses to 
this approach were inconsistent, with many participants not showing the aforementioned 
improvements to their speech output. Some studies attempted to identify why some PwPD 
had a poor response to the alteration (Dagenais, Southwood, & Mallonee, 1999; Lowit, 
Brendel, & Howell, 2006; Rousseau & Watts, 2002) but results were inconclusive.  
Most investigations into AAF treatment with PwPD suffer from similar limitations to those 
with other treatment methods, i.e. they mainly constitute single or multiple case studies 
without controlled comparisons with placebo or other treatment types. There are also few 
indications of the long-term effectiveness of AAF devices in this speaker group. Such 
information would be particularly important as informal reports allude to habituation effects 
that might diminish any positive results AAF might have on a speaker‟s intelligibility (c.f. 
data on PwS by e.g. Pollard, Ellis, Finan, & Ramig (2009)). Furthermore, previous studies 
generally did not report on how viable the devices were as actual therapy tools in relation to 
handling, maintenance and acceptance by the client.  
 
The aims of this study were therefore (1) to compare the long-term effects of traditional rate 
control therapy and AAF on speaking rate and intelligibility in PwPD with a presenting 
dysarthria and (2) to evaluate the viability of AAF as a treatment device for everyday use.  
 
Methodology 
Participants  
Ten speakers with idiopathic PD and a speech impairment severe enough to warrant 
treatment took part in the study. Exclusion criteria were the presence of significant dementia 
(MMSE score), a history of deep brain stimulation, and speech and language therapy for 
dysarthria symptoms during the last 12 months. In addition, the presence of speech and 
language problems other than those caused by PD was cause for exclusion. One exception 
was made where a client had an accompanying stutter. As AAF has been reported as 
beneficial for people who stutter, it was decided to include this person to look into the 
interaction of the stammer and the PD in response to AAF. Care was taken in the evaluation 
of the results that this speaker did not significantly influence the statistical outcome or 
qualitative data interpretation by running comparisons with and without his data. It was 
subsequently deemed appropriate to include him in all comparisons reported in this study. 
 
Participants comprised six males (mean age 62 years; age range 52 – 67 years) and four 
females (mean age 62 years; age range 49 – 71 years). Their dysarthria ranged from mild to 
moderate-severe, as evaluated by an experienced speech and language pathologist on the 
basis of oromotor performance (DDK and maximum performance tasks), and intelligibility 
for single words, sentence and passage reading as well as a monologue task. Since the post-
treatment assessments spanned a period of up to 18 months, it was unethical to ask speakers 
to remain on the same dose of medication for the full duration of the study. There were thus 
some changes to drug regime during the follow up period. In addition, two participants had to 
change their medication during one of the treatment phases. Reports in the literature on the 
effects of parkinsonian medication on speech are inconclusive, with some studies reporting 
improvements (De Letter, Santens, & Van Borsel, 2003; Sanabria et al., 2001; Vercueil, 
Linard, Wuyam, Pollak, & Benchetrit, 1999), some a status quo (De Letter, Santens, De Bodt, 
Boon, & Van Borsel, 2006; Goberman, & Coelho, 2002; Kompoliti, Wang, Goetz, Leurgans, 
& Raman, 2000) and some a worsening of dysarthria symptoms (Louis, Winfield, Fahn, & 
Ford, 2001, Murdoch, Chenery, Bowler, & Ingram, 1989; Rice, Antic, & Thompson, 2002). 
This suggests a highly individual response by speakers to medication and these two 
participants were thus not automatically excluded from the study. Instead, their speech 
characteristics were carefully monitored by the treating therapist who determined that no 
perceptually significant changes out of line with general improvement in therapy observed up 
to the point of medication change were evident. In addition, their profiles were examined in 
detail during data evaluation to ensure they did not bias the group results in any way. Table 1 
provides information on the participants, with details on their symptoms, as well as device 
use during the treatment phases. Information on medication reflects the status at the 
beginning of the study. 
 
Insert table 1 around here 
Study design  
An alternating treatment design was employed to compare the effects of traditional rate-
reduction therapy (TT) and altered feedback therapy (AAF). Each participant received both 
types of therapy which were separated by a 6-week no treatment period. Five speakers started 
with TT, the other five with AAF treatment. Participants were quasi-randomised to groups by 
virtue of entry to the study, i.e. they alternately started with either TT or AAF treatment. No 
performance variables (speech, cognition, etc.), age, gender or participant preference were 
thus used to determine group membership. Figure 1 details the timing of assessments and 
treatment periods. 
 
Insert Figure 1 about here  
 
Intervention 
Each intervention was delivered in once weekly sessions of about 50-60 minutes duration for 
six weeks. This regime adhered to the treatment model that clients would typically receive 
from the health service in the UK (Deane et al., 2008)
1
. To ensure full attendance and reduce 
the strain on the participants, sessions were offered in their own home. This is again not 
unusual as part of standard NHS treatment (Deane et al., 2008).  
 
Traditional therapy (TT) 
TT centred on identifying the most suitable strategy for reducing speech rate (SR), i.e. 
increasing pauses and / or stretching out articulation. The majority of speakers opted for the 
pause insertion technique. Tasks followed the widely described hierarchy of complexity, 
                                                     
1 The authors are not aware of any other formal studies into the nature of PD treatment in 
other parts of the world, however, anecdotal evidence suggests that the UK model is 
comparable to practices in a range of other countries.  
ranging from reading aloud short phrases to conversational speech. Phrasing exercises were 
integrated early on where inappropriate pause placement was used during rate reduction or 
during natural speech. In addition, self-appraisal skills were developed as quickly as possible 
through feedback and listening to recordings of their own voice. Where appropriate, other 
speech aspects in need of treatment, such as volume or intonational variation, were integrated 
into the treatment plan. Performance feedback was provided in line with motor learning 
principles (Maas et al., 2008; Schmidt & Bjork, 1996; Zimmerman & Kitsantas, 1997).  
Carryover was targeted by practising more everyday type speech tasks during the therapy 
sessions and encouraging patients to use the strategies learned in therapy in everyday speech 
through homework assignments. In addition, participants were encouraged to think of a label 
that personally defined their speaking style when speaking at their target rate. This aimed to 
encapsulate their best speech in one concept, which they could then use as a cue during 
practice and carryover. For example, participants labelled their reduced rate as their “laid 
back speech” or their “explaining voice”.  
 
Altered feedback therapy (AAF) 
AAF was delivered through a choice of two devices, the Smalltalk and the School DAF 
(http://www.casafuturatech.com). The benefit of the Smalltalk is that it delivers both DAF 
and FSF. It also has a „push to talk‟ facility which allows the user to activate the AAF only 
when they want to speak. This facility was also built into the School DAF by adding an 
external switch. Devices and headphones were provided to participants according to their 
individual needs. The choice of device depended on whether they were likely to use FSF or 
not. The headphones used by participants were either a Sennheiser PC131 full size binaural 
headset, Plantronics MX100S binaural cellphone earsets, Jabra EarWave Bud
™
 single 
earpiece headset, or a wireless Bluetooth headset (Jabra BT250v). Research has shown 
binaural input to be more effective than monaural in people who stammer (Stuart, 
Kalinowski, & Rastatter, 1997). Such issues of effectiveness were balanced with acceptability 
of wearing the device, interference with hearing aids and the participants‟ ability to handle 
the headphones. See table 1 for participants‟ choice of device, headset and preferred AAF 
setting. 
Early AAF therapy sessions were spent on determining which feedback type and setting had 
the best effect on rate whilst not being detrimental to naturalness and the processing of 
thought and speech. In most cases the AAF had an immediate effect in reducing speaking 
rate, and it was unnecessary to work on rate reduction strategies. Instead, intervention 
focused on practice using the device in various speaking tasks and situations, both during the 
session and at home, comparable to the therapy model for TT. In addition, intonational 
inflection and articulation were addressed if these were negatively influenced by the use of 
altered feedback.  
 
Recording and Analysis Procedures 
Recordings were obtained in participants‟ homes in quiet conditions. Recordings were timed 
to ensure that participants were performing at their optimum capacity. In cases where 
medication was wearing off during the recording, the assessor waited until the new dose had 
taken maximum effect before continuing with testing.  
Participants were seated twelve inches from a Beyerdynamic Microphone M58. Recordings 
were made digitally using a Tascam DA-P1 digital recorder and transferred at 48k sampling 
rate through SPDIF to a computer. Data were subsequently analysed with the Praat analysis 
system (Boersma & Weenink, 2006).  
 
 
Tasks and Measures 
Data evaluation focused on two speech parameters – speech rate and intelligibility. Speech 
rate was chosen as outcome measure as the main effect of AAF reported in the literature is a 
slowing of speech. Intelligibility is one of the primary clinical outcome measures used for 
therapy and it was thus most suited to assess change after treatment in the current study. It 
was important that these outcome measures be assessed in continuous speech tasks, as AAF 
is known to be less effective on short stretches of speech such as single words or short 
sentences. The evaluation of the current participant group also suggested that considerably 
differences could exist between intelligibility on single words/sentences and longer connected 
speech task. A reading passage and a monologue were thus chosen for the purpose of the 
current evaluation. Details on these tasks and measures as well as the feedback conditions are 
as follows: 
 
Tasks 
The reading tasks consisted of the “Cherry Tree” passage (Lowit et al., 2006) which was read 
aloud after participants had familiarised themselves with it. It is phonetically balanced and 
contains a range of utterance lengths. The monologue task involved reminiscence questions 
such as “Tell me how transport /leisure activities / school, etc. differ today from when you 
were a child”. Participants were asked a different stimulus question at each assessment point 
and for each feedback condition.  
 
Feedback Conditions 
The reading task was performed with three feedback conditions - no feedback (NF), delayed 
auditory feedback (DAF, 150ms delay) and frequency shifted feedback (FSF, ½ octave 
upward shift, c.f. Brendel et al., 2004). In addition, all post-AAF intervention assessments 
included an additional condition with their preferred AAF setting (PF) that had been 
established during therapy. The monologue task was only performed in the NF and PF 
conditions. The order of feedback conditions and tasks was randomised for each assessment 
to control for fatigue effects. 
In order to reflect natural carry over of the treatment strategies as much as possible, 
participants were not specifically instructed to reduce their speech rate during the 
assessments, but only to perform as best as they could. 
 
Outcome measures 
Speech rate was measured as the number of syllables produced per second including pauses. 
Due to a high degree of utterance and pause length in the monologue data, this measure was 
only calculated for the reading passage. The experimenter who processed the acoustic data 
was blind to treatment group, time of assessment and AAF condition. 10% of the data were 
re-analysed by a second experimenter. The results had a correlation coefficient of r =.444, 
p<.0005 indicating good inter-rater agreement.  
 
Intelligibility was measured in two different ways. For the reading passage direct magnitude 
estimation (DME, Whitehill, Lee, & Chun, 2002) was employed. This helped to counteract 
the effects of listener familiarity with the passage. Listeners were presented with groups of 5 
samples, i.e. the standard and four samples to be rated. As the purpose of this evaluation was 
to measure change over time rather than comparing speakers with each other, each speaker 
acted as their own standard. The NF condition of the first assessment was used for this 
purpose. For the monologue, listeners used a 9 point Likert scale developed by Dobinson 
(2007) which integrates perceptions of intelligibility
2
 as well as listener effort.  
Ten final year SLP students acted as judges. They were familiar with dysarthric speech and 
were trained in DME and the Likert scale. To evaluate the AAF intervention, only the PF 
conditions were rated as these were most reflective of treatment outcome. Judges were blind 
to treatment group, assessment time and feedback condition. Inter-rater reliability for 
intelligibility ratings was assessed by calculating the intraclass correlation coefficient (ICC) 
(Shrout & Fleiss, 1979) for the 10 listeners‟ scores for the first recording of the monologue. 
Agreement between listeners was good with a coefficient of r=.89, p<0.01. Due to the nature 
of the DME rating, reliability measures could not be performed for the assessment of reading. 
 
All procedures complied with UK National Research Ethics Service (NRES) ethical 
guidelines. 
 
 
Results 
Changes over time 
To evaluate whether participants changed their speech rate or intelligibility over time, a 
mixed ANOVA was performed for each of these variables, with time as the within subject 
and therapy group (AAF or TT as first treatment) as the between subject factor. The analysis 
was performed with the no feedback data as these could best indicate whether any of the 
treatments had resulted in carry-over to naturalistic speech.  
                                                     
2
 The evaluation of the monologue task might be more accurately described as 
comprehensibility, as listeners were given the context of the speaker‟s discourse. However, 
the term intelligibility will be used for the remainder of this paper to simplify reference to the 
evaluations of the two connected speech task.  
Table 2 shows the group results for rate and intelligibility across time. For the reading task 
main effects for time were not significant for either variable (speech rate: Wilk‟s Lambda = 
.16, F (6,2) = 1.73, p = .411, Partial Eta Squared = .84; intelligibility: Wilk‟s Lambda = .39, F 
(6,3) = .786, p = .635, Partial Eta Squared = .61), or for group (speech rate: F(1,7) = .227, p = 
.648, Partial Eta Squared = .03; intelligibility F(1,8) = .111, p = .748, Partial Eta Squared = 
.01). There were also no significant interaction effects between therapy group and recording 
time for the reading data (speech rate: Wilk‟s Lambda = .23, F (6,2) = 1.09, p = .551, Partial 
Eta Squared = .77; intelligibility: Wilk‟s Lambda = .18, F (6,3) = 2.29, p = .265, Partial Eta 
Squared = .82). The statistical results thus suggest that there were no significant changes in 
reading without altered feedback for speech rate or intelligibility within each group, 
irrespective of which type of treatment participants started with. The evaluation of 
intelligibility in the monologue task yielded the same non-significant outcomes (interaction 
effect Wilk‟s Lambda = .43, F(6,3) =.671, p = .691 Partial Eta Squared = .57; main effect for 
time: Wilk‟s Lambda = .22, F(6,3) = 1.78, p = .340, Partial Eta Squared = .78; main effect for 
group F(1,8) = .945, p = .359, Partial Eta Squared = .11). 
 
Insert table 2 around here 
 
AAF treatment versus traditional therapy 
Although the ANOVA results reported above suggested that there were no significant 
changes over time, individual profiles suggested otherwise for at least some of the 
participants (see below). To evaluate whether the observed changes followed any patterns 
with regard to treatment type, the mean of the two pre-therapy measures was compared to the 
immediate post-intervention results for the NF data. For this analysis, the percentage 
difference between the above measurement points was calculated for each participant and 
treatment type for speech rate and intelligibility. The Wilcoxon Signed Rank Test was then 
applied to determine whether TT and AAF treatment differed significantly in the amount of 
change effected by the participants for each outcome measure (see Table 3 for group range, 
means and SDs). Again, no significant difference could be detected for speech rate (p = .214), 
reading intelligibility (p = .445) or monologue intelligibility (p = .445), indicating that the 
two types of treatment did not affect speech output differentially when tested in the NF 
condition.  
Insert table 3 around here 
 
 
Feedback conditions 
In order to investigate how the AAF settings affected speech rate and intelligibility, these 
variables were compared across the different feedback conditions. For intelligibility, only the 
NF and PF conditions had been rated. As different numbers of PF recordings were available 
for speakers depending on which treatment group they belonged to, NF data were only used 
from assessments were a PF recording had also been taken, resulting in equal numbers of data 
points for NF and PF conditions. Also, as the focus of this comparison was feedback type 
independent of treatment group or assessment point and previous analysis had already 
indicated that performance did not change significantly over time, the NF and PF data were 
pooled across time and groups, resulting in two sets of intelligibility data, NF and PF. As 
there were only two variables to be compared, the Wilcoxon Signed Rank Test was 
performed for both reading and the monologue. 
Speech rate had only been analysed for the reading task, but for all four feedback conditions 
(NF, DAF, FSF and PF). The data were again pooled across group and time for those 
assessment points where all four feedback conditions were completed by the participants. A 
one-way repeated measures ANOVA was performed, with speech rate representing the 
dependent and the feedback type the independent variable.  
The Wilcoxon Test results indicate that there was no significant difference in intelligibility 
between the no feedback and the preferred feedback conditions for reading (p=.677) or the 
monologue (p=.122) suggesting that speakers did not benefit from AAF as a group. The 
speech rate comparisons between the feedback conditions, on the other hand, resulted in a 
significant effect for feedback type (Wilk‟s Lambda = .15, F(3,18) = 34.84, p < .0005, Partial 
Eta squared = .85), with AAF conditions showing slower rates than the NF condition. 
Bonferroni post hoc tests indicate significant differences between all feedback conditions (the 
significance value was below p = .002 in all cases) with the exception of FSF and PF, which 
showed similar speech rates (p = .695). The slowest speech rate was observed with the DAF 
setting of 150ms, followed by the FSF and PF and finally the NF condition (see Table 4). 
Insert table 4 around here 
 
Habituation Effects 
It became apparent at the post-intervention recordings that a number of speakers changed 
their preferred AAF settings over time, particularly when they had started with AAF therapy 
and had been using the device for some time. This suggests a certain degree of habituation to 
the feedback. The continued positive effects achieved by relatively changes in setting, as well 
as the fact that the preset DAF and FSF settings still elicited the same response observed in 
earlier assessments suggest that the habituation effects could be reduced or eliminated by 
changes to the AAF setting.  
 
Individual participant profiles 
Despite the negative outcomes from the group data, some participants did show 
improvements in intelligibility as a result of therapy. Given that there exists no agreed level 
of percentage change that is recognised as representing a clinically significant level of 
improvement, this conclusion was based on the observation that there was a consistent 
difference in performance over time and/or that changes were reflected in both the reading 
and the monologue data. 
Four of the ten participants had higher intelligibility ratings in the no feedback condition after 
the first phase of therapy and were able to maintain this level across the remaining 
assessments, i.e. into the 6 months follow up period. Interestingly, their intelligibility 
improved irrespective of whether they had received AAF or TT.  
Another three speakers showed improved levels of intelligibility with AAF at the preferred 
feedback setting, without showing improvements in their no feedback speech. Again, these 
improvements were maintained across all post-intervention recordings.  
The remaining three speakers did not change over time and thus showed little benefit from 
either traditional or AAF therapy.  
No pattern could be identified between improvements in speech performance and alterations 
in drug regime, suggesting that medication changes did not significantly affect the evaluation 
of treatment efficacy in the current speaker group. In addition, the participant with a stutter 
showed no improvement in intelligibility despite personal reports that he considered the AAF 
device as enhancing his communication. 
The question of decline over time was considered individually as well. With the exception of 
two speakers, there was no clear indication that performance levels decreased significantly 
over the course of the study. There was also no evidence of any relationship between the 
severity of the participants‟ dysarthria or PD symptoms and the presence or rate of decline 
over the investigated period. Due to the small numbers of participants involved in these 
evaluations, no statistical analyses were performed to confirm these assumptions. 
 
 
Discussion 
This study employed an alternate treatment design to study the effects of traditional methods 
and AAF on rate reduction and intelligibility in a group of ten speakers with idiopathic PD. 
Speech rate measures revealed that participants showed no improvements over time in the 
self-paced NF condition, but AAF induced significantly slower speech at any given time. 
These rate reductions did not automatically translate into intelligibility improvements though. 
More generally, group statistics revealed no significant improvements after either therapy 
phase for intelligibility. However, individual data evaluation comparing results across tasks, 
feedback conditions and treatment groups revealed that a considerable number of participants 
did in fact benefit from both forms of treatment. They also showed that some speakers‟ 
performance declined over time, while others‟ remained stable. There was some evidence for 
habituation to AAF, particular in long-term use, but this could be counteracted by making 
small adjustments to the device settings. 
One interesting result was the fact that intelligibility in the no feedback condition improved 
for some speakers after the first treatment phase, irrespective of which type of therapy they 
had received. This was not expected as no specific advice on speech without feedback was 
given during AAF treatment. The result could thus reflect a generic treatment effect, where 
participants generalised advice given for AAF speech, or possibly a placebo effect, in that 
increased attention to the participant might have resulted in improved speech output. Due to 
the small participant group no conclusions can be drawn about this observation at the current 
stage, but this issue should be considered in the design of future larger scale treatment 
evaluation studies. 
 
Traditional Therapy 
The lack of success of traditional methods was somewhat surprising as previous studies have 
reported success of similar methods to the current study for at least a small number of 
speakers, both in terms of rate reduction and intelligibility improvements (Hammen et al., 
1994; Le Dorze et al., 1992; Yorkston et al., 1990).  
One possible reason for this discrepancy is the post-treatment assessment method used in this 
study. Participants were not specifically asked to reduce their speech rate during the speaking 
tasks, in order to evaluate to what degree they would implement strategies learnt during 
therapy spontaneously in the assessment situation. Although they did not succeed in this, 
notes taken during the treatment sessions clearly indicate that speakers were successful in 
reducing rate in the clinical context. Current assessment data thus need to be interpreted as 
indicating that the current group did not generalise the traditional methods successfully to 
outside contexts, rather than not being successful at all in reducing speech rate. In addition, 
the individual data suggest that some speakers did in fact show some improvements in 
intelligibility. Individual response variability is thus an important issue to be taken into 
account in small scale studies such as the current.  
Rate reduction methods are another factor to consider in comparing the current with previous 
results. The current TT treatment largely relied on self-pacing, as this was most appropriate 
for the participant group (only one speaker started to use an alphabet chart towards the end of 
the study period). This differs to the techniques used in some of the other reports in the 
literature, which included external pacing techniques both in treatment and for assessment. 
One other issue that could have influenced the current results is the severity of dysarthria. 
Those with milder severity were able to complete the treatment regime and practice slow rate 
with longer reading passages and spontaneous dialogues. Others, however, would have 
needed more than six sessions and were unable to implement the strategies in longer stretches 
of speech by the end of treatment. It is thus possible that those with milder severity did not 
feel the need to reduce rate to perform well on the tasks, and those with more severe 
problems were yet unable to do so. In addition, some speakers‟ intelligibility levels were still 
quite high at the start of the study, and they thus had less scope for improvement than those 
whose speech was impaired more severely. Another speaker related aspect that could have 
affected response to treatment was the cognitive state of the speaker, although no particular 
pattern could be detected that linked cognitive ability to therapy success in this small sample. 
Intensity of treatment should also be considered. The success of LSVT has focused attention 
on the importance of treatment frequency, which was relatively low in the current study 
compared to LSVT. To what degree this affected outcome cannot be assessed on the basis of 
the current results, but the issue should be considered in future research. Related to this is the 
issue of home practice. Participants were asked to indicate how much they practiced at home 
in this study. However, this information was insufficiently complete to be related to treatment 
outcome. It would be beneficial if future larger scale studies would build in ways of reliably 
collating such information. 
A final aspect to consider in relation to treatment success is the fact that whilst few 
participants showed significant improvements after therapy, the performance of most 
speakers also did not decline to a great degree over the 18 months of the study. In the light of 
PD being a degenerative disease, this could potentially indicate that whilst therapy did not 
help speakers to improve on their current state, it might have allowed them to maintain the 
status quo for longer. As decline over time in overall PD severity was not monitored in detail, 
this notion has to be interpreted with caution though.  
The results closely reflect those of a treatment study on participants with dysarthria following 
stroke (Mackenzie & Lowit, 2007). Group results were equally inconclusive in that study 
despite indications that about half of the nine participants showed some communicative gain 
from treatment. The paper stresses the difficulty of demonstrating significant effects with 
small, heterogeneous participant groups, a limitation that also applies to the current 
investigation. 
 
 
AAF Therapy 
This cohort‟s success rate of AAF is comparable to that in the literature, i.e. around one third 
of participants showed benefits for rate reduction and intelligibility (Downie et al., 1981; 
Dagenais, Southwood & Lee, 1998; Lowit et al., 2006). In light of the current and previous 
results, one can thus assume that around 25 to 30% of PwPD will show intelligibility benefits 
from the use of AAF. On this basis, AAF could be considered a viable treatment option for 
these speakers.  
When assessing clients for suitability of AAF treatment, clinicians should keep in mind that 
current results showed that attempts to modify the participants‟ speech output to achieve 
greater intelligibility improvements were unsuccessful, i.e. a positive response to the device 
could not be trained during treatment. Clients should thus show an immediate beneficial 
response to AAF to be considered for this technique.  
One advantage of the immediacy of the AAF effect is that the speed of progression through 
tasks is noticeably faster than for traditional treatment. In the current study, less than the 6 
sessions offered would generally have sufficed, making AAF a highly cost-effective 
treatment. It should be noted though that some treatment sessions need to be provided in 
order to provide specific advice on usage, practice different speaking situations and establish 
the most appropriate AAF setting, which might differ according to speaking context.  
 
Habituation Effects 
There has been some concern amongst clinicians regarding the long-term use of AAF due to 
habituation. Data from the speakers who responded positively to AAF and continued using it 
show that the effect was maintained over this time. However, changes were made to the 
settings to ensure continued benefit from the use of the device, thus suggesting a certain 
degree of habituation to the feedback. On the positive side relatively small changes to the 
setting resulted in renewed speech improvements, suggesting that clients might benefit from 
AAF for reasonable amount of time despite habituation effects. In addition one participant 
reported having a „break‟ from using the device now and again for a period of one or two 
days. This renewed the effects when he resumed using it.  
 
Device Usability 
A number of issues emerged from this study that have to be taken into account when using 
AAF devices with PwPD. Acceptability of using an external, visible aid is one of them. 
Although the actual AAF devices can be hidden from view, the headsets can not. Whilst the 
binaural headsets resulted in the best feedback, few speakers would wear these in public and 
thus opted more for the less obtrusive, monoraural headsets. A balance thus had to be struck 
between effectiveness and acceptability to promote device usage. Other types of AAF 
devices, for example the SpeechEasy system (www.speecheasy.com) that is fitted straight 
into the speaker‟s ear (Wang, Verhagen, & de Vries, 2005) might alleviate such concerns. A 
more technical problem associated with headset choice was the fact that the AAF can 
interfere with hearing aids. In the case of monaural aids, a monaural headset could be used in 
the other ear. In the case of binaural hearing aids, the full size Sennheiser headset was able to 
eliminate the interference in some cases.  
There were also problems associated with the handling of the devices. Originally developed 
for PwS, the devices do not necessarily take into account issues arising from tremor and 
impairment of fine motor problems experienced by the PD client population. This applied 
particularly to the Smalltalk device used in this study, which had very small buttons and dials 
to operate. Some of these limitations were overcome by making adjustments to the devices, 
such as adding on larger switches. The push to talk facility was valued by users as it 
eliminates distortions of background noise and the speech of the communication partner(s). 
However, there were problems associated with its use. In addition to the design issues such as 
participants having to locate a small button amongst other dials, operating the PTT facility 
also introduces an additional task that has to be coordinated with speech. One thus has to be 
careful that the benefits of this feature for general acceptability of using the device still 
outweigh any secondary problems caused by it, particularly for speakers who experience 
some level of cognitive decline.  
 
 
In summary, the results of this study suggest that traditional as well as AAF rate reduction 
techniques can have long-term beneficial effects on intelligibility on a subset of PwPD. 
Dysarthria severity could not predict how well a speaker would respond to treatment and to 
what degree their performance might decline over time due to general degeneration resulting 
from the disease. Larger scale, well controlled studies are required of a range of rate 
reduction methods, combined with placebo/attention control and LSVT
®
 treatment to identify 
the value of each type of treatment against variables such as PD severity, cognitive status and 
presenting symptoms of the dysarthria. 
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Tables & Figures and Captions: 
 
Table 1: Participant profile, indicating age, gender, dysarthria symptoms and severity, PD 
severity (H&Y score), cognitive score (MMSE score), treatment sequence including device 
setting and headset choice, and medication. All information relates to the status at the start of 
study. 
 
Table 2: Group means (and SD) for speech rate and intelligibility measures for reading and 
monologue tasks for the no feedback (NF) condition across the seven assessment points. 
 
Table 3: Group range, means and SDs for the percentage change from baseline to immediate 
post-treatment measures for speech rate and intelligibility in the reading and monologue tasks 
for the no feedback (NF) condition. 
 
Table 4: Group means (and SDs) for speech rate and intelligibility across the various 
feedback conditions. 
 
Figure 1: Study design indicating assessment points and treatment phases. 
 
Participant 
Number 
Age Sex Dysarthria symptoms and severity H&Y 
score 
MMSE 
score 
Treatment sequence and devices Medication  
PD1 49 F Very rapid and festinant speech / 
Flattened inflection / Slight 
hypernasality (3). 
1 29 AAF-TT 
Smalltalk, 125ms delay, Jabra 
EarWave Bud headset. 
Requip 3mg tds 
PD2 64 M Slightly rapid speech / Sometimes 
reduced inflection (1). 
1 30 AAF-TT 
Smalltalk, 125ms delay, Jabra 
EarWave Bud headset.  
Entacapone 200mg daily, Madopar 62.5 daily, 
Ropinerole 1mg x 5, Stalevo x 2, Sinemet 125 mg 
daily 
PD3 67 M Rapid bursts of speech with some 
festination / Slightly reduced 
inflection and volume / Stammer (2). 
2 28 AAF-TT 
Smalltalk, 100 ms delay, Jabra 
Bluetooth headset 
Ropinerole hydrochloride 5mg tds; Ropinerole 
hydrochloride 1mg daily; Sinemet plus qds; half-
sinemet CR nocte. Amitiriptyline 10mg daily 
PD4 69 M Slightly reduced rate / Quiet voice 
with reduced inflection / Mild 
hypernasality (1). 
1 29 AAF-TT 
Smalltalk, ¼ octave increase, Jabra 
Earwave Bud headset 
Nil  
PD5 64 M 
Quiet voice / Indistinct articulation / 
Hypernasality (3).  
4 29 AAF-TT 
School DAF, 175 ms delay, Jabra 
EarWave Bud headset  
Apomorphine 100mg 20ml daily; Sinemet plus 
(25/100) x 9 daily; Zopiclone 7.5mg nocte; 
Quetiapine 12.5mg nocte; Madopar dispersible 
125mg daily; Diazepam 2mg nocte. 
PD6 71 F Rapid rate / Decreased inflection and 
quiet voice (3). 
3 29 TT-AAF 
Smalltalk, 125ms delay, Jabra 
EarWave Bud headset. 
Sinemet plus 25/100mg x1, Sinemet CR 50/200mg 
x2, Risedronate Sodium 35mg x1 weekly 
PD7 52 M Slightly rapid speech / Quiet voice and 
reduced inflection (2).  
2.5 30 TT-AAF 
Smalltalk, 90 ms delay & ¼ octave 
increase, Jabra EarWave Bud headset 
Sinemet Plus x1, Entacapone 200mg qds, Zelopar 
1.25mg, Ropinerole 8mg tds. 
PD8 66 M Slightly rapid speech / Quiet voice /  
Slightly reduced inflection (2).  
3 29 TT-AAF 
Smalltalk, ¼ octave increase, 
Sennheiser binaural headset 
Sinemet plus 6 daily, Mirapexin 250mg, Simvastativ 
20mg, Mirapexin 1 mg x 2, Sinemet CR x1 nocte. 
Glycerole trinitrate 400 mcg. Rasagaline 1mg daily 
PD9 63 F Rapid speech / Very quiet voice with 
poor inflection / Slight hypernasality / 
Poor breath support / Poor 
intelligibility (4).  
5 29 TT-AAF 
Smalltalk, 200 ms delay, Jabra 
EarWave Bud headset. 
Sinemet plus, Domperidone 10mg mane, Symmeterel 
100mg mane, Thyroxine 100mcg mane, Frusemide 
20mcg nocte, Amitriptyline 10mg nocte, Diazepam 
nocte, Amoxocylin mane 
PD10 63 F Rapid speech (1).  3 30 TT-AAF 
Smalltalk, ¼ octave increase, Jabra 
EarWave Bud headset 
Stavelo 50/125/200 x 8, Selegiline 5mg, Pergolide 
1mg tds, Madopar 62.5 as reqd. 
Dysarthria Severity: 1 = mild, 2 = mild–moderate, 3 = moderate, 4 = moderate-severe, 5 = severe; H&Y = Hoehn & Yahr (1967) score, MMSE = Minimental 
State Examination (Folstein, Folstein, & McHugh, 1975), AAF = altered auditory feedback therapy; TT = traditional therapy 
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Speech rate: 
Reading 
3.73 
(0.60) 
3.85 
(0.61) 
3.47 
(0.50) 
3.56 
(0.43) 
3.55 
(0.56) 
3.46 
(0.76) 
3.92 
(0.24) 
Intelligibility: 
Reading 
100 
(0) 
99 
(20) 
110 
(11) 
109 
(16) 
116 
(15) 
116 
(20) 
114 
(31) 
Intelligibility: 
Monologue 
7.1 
(2.1) 
7.0 
(2.1) 
7.3 
(2.0) 
7.1 
(2.3) 
7.0 
(2.0) 
7.1 
(1.9) 
6.9 
(2.3) 
 
Speech rate: syllables/second, Reading intelligibility: DME rating, Monologue Intelligibility: 0-9 Likert 
scale. NB: The DME rating for Reading Intelligibility at Baseline 1a was used as the evaluation standard, so 
each speaker received a value of 100 for this sample. 
Tab 2  
 Treatment Type: 
Reading:  
Speech rate 
Reading: 
Intelligibility 
Monologue: 
Intelligibility 
TT treatment Range: -5.6 - +21.5 
Mean: 6.2 
SD: 9.9 
Range: -77 - +15 
Mean: -16.2 
SD: 30.85 
Range: -8.4 - +17.1 
Mean: 1.2 
SD: 7.2 
AAF treatment Range: -17.9 - +16.4 
Mean: -1.7 
SD: 9.6 
Range: -47 - +23 
Mean: -8.1 
SD: 20.42 
Range: -33.3-+10.0 
Mean: -6.0 
SD: 13.1 
NB: Negative values signal an increase in speech rate/intelligibility from baseline to post-treatment 
assessment.  
Tab 3 
 
 
 Feedback Type NF PF DAF FSF 
Speech Rate: 
Reading 
3.6 
(0.2) 
3.2 
(0.2) 
2.7 
(0.3) 
2.9 
(0.4) 
Intelligibility:  
Reading 
113 
(20.8) 
110 
(19.8) 
  
Intelligibility:  
Monologue 
7 
(1.8) 
8 
(1.8) 
  
 
Speech rate: syllables/second, Reading intelligibility: DME rating, Monologue Intelligibility: 0-9 Likert 
scale; NF – no feedback, PF = preferred feedback, DAF = delayed auditory feedback, FSF = frequency 
shifted feedback. 
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